Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
Innate Pharma announces publication of monalizumab research in the prestigious “Cell” journal widening the horizon of immune checkpoint inhibitors
SITC 2018: further analyses of the Phase II study of the combination of monalizumab and cetuximab in head and neck patients show encouraging survival data in both subgroups of IO-naïve and IO-pretreated SCCHN patients
Clinical data featured as oral presentations at two major upcoming oncology conferences
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
Innate Pharma announces Phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 Congress
Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi®) in solid tumors
